Sequence 20 from Patent US 20110159022

General Information


DRACP ID  DRACP01319

Peptide Name   Sequence 20 from Patent US 20110159022

Sequence  AEWAWGPCTPSSKDC

Sequence Length  15

UniProt ID  P21741 

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01319

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C71H100N18O23S2

Absent amino acids  FHILMNQRVY

Common amino acids  ACPSW

Mass  188770

Pl  4.18

Basic residues  1

Acidic residues  2

Hydrophobic residues  4

Net charge  -1

Boman Index  -1867

Hydrophobicity  -66.67

Aliphatic Index  13.33

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  11125

Absorbance 280nm  794.64

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0159022 A1

Patent Title  Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.

Other Iinformation  Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status: Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;

Other Published ID  CA2728459A1  CN102123731A  EP2296697A1  WO2009153463A1 




DRACP is developed by Dr.Zheng's team.